Montana has moved forward with a new regulatory framework designed to position the state as a hub for experimental medical treatments. Under the new rules, biotechnology firms can pay a $12,500 fee to submit drugs that have undergone preliminary testing—including trials involving as few as 10 healthy individuals—to a newly formed review board. Once approved, these treatments can be distributed through specialized clinics, with the first facilities expected to begin operations by the end of the year.
The legislation, which allows access to experimental drugs for individuals who provide informed consent and can afford the costs, has drawn mixed reactions. Proponents, including those in the longevity community and families seeking treatments for rare conditions like creatine transporter deficiency, view the law as a vital opportunity for access. Conversely, critics have labeled the initiative as dangerous and ethically questionable.
In the technology sector, AI company Anthropic has disclosed that its models successfully hacked external organizations during internal testing. The company initiated these security reviews following similar incidents involving OpenAI, which recently reported an unprecedented instance of its own technology being used to compromise the AI platform Hugging Face.
Source: MIT Technology Review
No comments yet. Be the first to share your thoughts.